Andrew Pierce Translational Biology Crescendo Biologics Biography Publications Institution JoVE Articles Andrew Pierce Andrew has been leading translational biology teams for over 18 years with international industrial experience developing both small and large molecule oncology drugs. He began his career on the faculty of the University of Kentucky before joining N of One Therapeutics, MedImmune (USA) and subsequently AstraZeneca (UK). Andrew has brought multiple therapeutic candidates into and through clinical development including immunotherapies, antibody/drug conjugates, DNA damage/repair modulators and classical cell signalling inhibitors.Andrew has a BSci degree from the University of Toronto in Canada, and a PhD in molecular genetics from the University of North Carolina at Chapel Hill. He has published over 40 papers in peer-reviewed journals and serves on the Molecular and Cellular Medicine Board of the MRC. Publications Evaluation of UV-C Decontamination of Clinical Tissue Sections for Spatially Resolved Analysis by Mass Spectrometry Imaging (MSI) Analytical Chemistry. 02, 2021 | Pubmed ID: 33474935 SLFN11 Informs on Standard of Care and Novel Treatments in a Wide Range of Cancer Models British Journal of Cancer. Mar, 2021 | Pubmed ID: 33339894 A Guide to Naming Human Non-coding RNA Genes The EMBO Journal. 03, 2020 | Pubmed ID: 32090359 The Gene Cluster Instability (GCI) Assay for Recombination Methods in Molecular Biology (Clifton, N.J.). Month, 2020 | Pubmed ID: 31989572 The Sister Chromatid Exchange (SCE) Assay Methods in Molecular Biology (Clifton, N.J.). Month, 2020 | Pubmed ID: 31989571 Improved Therapeutic Window in -mutant Tumors with Antibody-linked Pyrrolobenzodiazepine Dimers with and Without PARP Inhibition Molecular Cancer Therapeutics. 01, 2019 | Pubmed ID: 30352801 PRAD50: a Novel and Clinically Applicable Pharmacodynamic Biomarker of Both ATM and ATR Inhibition Identified Using Mass Spectrometry and Immunohistochemistry British Journal of Cancer. 11, 2018 | Pubmed ID: 30385821 Potent Immune Modulation by MEDI6383, an Engineered Human OX40 Ligand IgG4P Fc Fusion Protein Molecular Cancer Therapeutics. 05, 2018 | Pubmed ID: 29545330 Targeting the Kinase Activities of ATR and ATM Exhibits Antitumoral Activity in Mouse Models of MLL-rearranged AML Science Signaling. 09, 2016 | Pubmed ID: 27625305 ATM Protein is Deficient in over 40% of Lung Adenocarcinomas Oncotarget. 09, 2016 | Pubmed ID: 27259260 Preparation of Peripheral Blood Mononuclear Cell Pellets and Plasma from a Single Blood Draw at Clinical Trial Sites for Biomarker Analysis Paola Marco-Casanova1, Natalia Lukashchuk1, Benedetta Lombardi1, Veerendra Munugalavadla2, Melanie M. Frigault3, Elizabeth A. Harrington1, J. Carl Barrett3, Andrew J. Pierce1 1Translational Medicine, R&D Oncology, AstraZeneca, 2Acerta Pharma, AstraZeneca Group, 3Translational Medicine, R&D Oncology, AstraZeneca JoVE 60776 Medicine
Preparation of Peripheral Blood Mononuclear Cell Pellets and Plasma from a Single Blood Draw at Clinical Trial Sites for Biomarker Analysis Paola Marco-Casanova1, Natalia Lukashchuk1, Benedetta Lombardi1, Veerendra Munugalavadla2, Melanie M. Frigault3, Elizabeth A. Harrington1, J. Carl Barrett3, Andrew J. Pierce1 1Translational Medicine, R&D Oncology, AstraZeneca, 2Acerta Pharma, AstraZeneca Group, 3Translational Medicine, R&D Oncology, AstraZeneca JoVE 60776 Medicine